Jubilant Pharmova Limited has informed the Exchange regarding Outcome of Board Meeting held on May 16, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited consolidated and standalone results for Q4 and FY ended March 31, 2025, along with a clean (unmodified) auditor's opinion from Walker Chandiok & Co. Consolidated revenue from operations grew about 7.9% to ₹72,345 crore from ₹67,029 crore, while net profit surged to ₹8,363 crore from ₹727 crore, though this includes a one-time net exceptional gain of ₹3,595 crore (mainly ₹6,715 crore gain from sale of SOFIE stake, offset by closure costs at Salisbury, Montreal facility expenses, and inventory provisions). Profit before exceptional items and tax rose roughly 83% to ₹6,211 crore, reflecting strong performance in Radiopharma, Allergy Immunotherapy, and CDMO-Sterile Injectables segments. The board recommended a final dividend of ₹5 per share (500%), with record date set for July 25, 2025.
Positives include robust core earnings growth, large dividend, and significant debt reduction (long-term borrowings fell from ₹31,671 crore to ₹21,503 crore) using SOFIE sale proceeds. Watch items: Generics segment still in loss (though narrowing) and headline PAT is flattered by one-time gains, so underlying sustainability of profits is the key consideration.